Journal article · 2010 · Open access

Antipsychotics and Schizophrenia: From Efficacy and Effectiveness to Clinical Decision-Making

George Foussias, Gary J. Remington

The Canadian Journal of Psychiatry, 55(3), 117–125 · Published 1 March 2010 · DOI 10.1177/070674371005500302

Open PDFView at the publisherCite this paper

In brief

“Antipsychotics and Schizophrenia: From Efficacy and Effectiveness to Clinical Decision-Making” is a 2010 journal article by George Foussias and Gary J. Remington, published in The Canadian Journal of Psychiatry. OpenAlex counts 71 citations as of 20 November 2026. It is open access: the full text is free to read at The Canadian Journal of Psychiatry.

Citations
71
Most cited in
2020 (7)
Field-weighted impact
6.05
References
26
Authors
2

Abstract

OBJECTIVE: To comprehensively review the 2 recent and large antipsychotic effectiveness trials for treatment of schizophrenia: the United Kingdom's Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS), and the National Institute of Mental Health-initiated Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. METHOD: We present a review of the rationale, methodology, and findings to date from the CUtLASS and CATIE schizophrenia trials, including all primary and secondary outcomes. RESULTS: The primary findings from both trials, CUtLASS and CATIE, suggest that first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs) are equally effective in the treatment of schizophrenia. The exception is in treatment-resistant populations where clozapine exhibits superiority, compared with other SGAs. In the CATIE trial, there is a suggestion that olanzapine is superior in effectiveness, compared with other nonclozapine SGAs, although this seems to be mediated by past history of olanzapine use, and carries with it increased weight gain and metabolic adverse events. From a cost-effectiveness perspective, there is no evidence that SGAs are superior to FGAs, with findings suggesting the possibility that FGAs may be superior. CONCLUSION: Past efficacy trials have strongly supported the position that SGAs are superior to FGAs in the treatment of schizophrenia and in side effect profile. Two large independent effectiveness trials, CUtLASS and CATIE, have offered a strong challenge to these claims. Both suggest that SGAs, except clozapine in the treatment-resistant population, offer little, if any, clinical benefits, and, moreover, harbour their own significant side effects.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Foussias, G., & Remington, G. J. (2010). Antipsychotics and Schizophrenia: From Efficacy and Effectiveness to Clinical Decision-Making. The Canadian Journal of Psychiatry, 55(3), 117–125. https://doi.org/10.1177/070674371005500302

MLA 9

Foussias, George, and Gary J. Remington. “Antipsychotics and Schizophrenia: From Efficacy and Effectiveness to Clinical Decision-Making.” The Canadian Journal of Psychiatry, vol. 55, no. 3, 2010, pp. 117–125. https://doi.org/10.1177/070674371005500302.

Chicago

Foussias, George and Gary J. Remington. 2010. “Antipsychotics and Schizophrenia: From Efficacy and Effectiveness to Clinical Decision-Making.” The Canadian Journal of Psychiatry 55 (3): 117–125. https://doi.org/10.1177/070674371005500302.

Harvard

Foussias, G. and Remington, G. J. (2010) ‘Antipsychotics and Schizophrenia: From Efficacy and Effectiveness to Clinical Decision-Making’, The Canadian Journal of Psychiatry, 55(3), pp. 117–125. doi:10.1177/070674371005500302.

IEEE

G. Foussias and G. J. Remington, “Antipsychotics and Schizophrenia: From Efficacy and Effectiveness to Clinical Decision-Making,” The Canadian Journal of Psychiatry, vol. 55, no. 3, pp. 117–125, 2010, doi: 10.1177/070674371005500302.

BibTeX

@article{foussias2010antipsychotics,
  title     = {{Antipsychotics and Schizophrenia: From Efficacy and Effectiveness to Clinical Decision-Making}},
  author    = {Foussias, George and Remington, Gary J.},
  journal   = {The Canadian Journal of Psychiatry},
  year      = {2010},
  volume    = {55},
  number    = {3},
  pages     = {117--125},
  doi       = {10.1177/070674371005500302},
  url       = {https://doi.org/10.1177/070674371005500302}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201544
201633
201744
201833
201911
202077
202122
202211
202311
202511

Its field-weighted citation impact is 6.05: it has been cited 6.05 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment

  • schizophrenia
  • antipsychotic drugs
  • atypical antipsychotics
  • typical antipsychotics
  • cutlass
  • CATIE
  • clozapine
  • olanzapine

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Foussias, G., & Remington, G. J. (2010). Antipsychotics and Schizophrenia: From Efficacy and Effectiveness to Clinical Decision-Making. The Canadian Journal of Psychiatry, 55(3), 117–125. https://doi.org/10.1177/070674371005500302

How many times has this paper been cited?

71 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at The Canadian Journal of Psychiatry: sign in and open the PDF from this page.

Who wrote this paper?

George Foussias, Gary J. Remington.

What is the DOI of this paper?

10.1177/070674371005500302, permanently at https://doi.org/10.1177/070674371005500302. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.